Novartis | NOVN - Cash And Equivalent


Novartis reported $6.88B in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
AbbVie USD 9.39B 4.16B Mar/2026
Alcon AG USD 1.58B 80M Mar/2026
Almirall EUR 337.77M 14.83M Dec/2025
Amgen USD 12.04B 2.91B Mar/2026
AstraZeneca USD 7.56B 1.85B Mar/2026
Autolus Therapeutics Ltd USD 130.92M 26.79M Mar/2026
Bayer EUR 6.67B 774M Dec/2025
Biogen USD 3.38B 374.2M Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Eli Lilly USD 5.28B 1.99B Mar/2026
Fresenius EUR 1.31B 81M Dec/2025
Fresenius Medical Care EUR 1.24B 343.37M Mar/2026
Genmab DKK 1.72B 46M Dec/2025
Gilead Sciences USD 7.56B 234M Dec/2025
GlaxoSmithKline GBP 3.44B 292M Mar/2026
GRIFOLS EUR 801M 242.31M Dec/2025
Hikma Pharmaceutical USD 236M 48M Jun/2025
J&J USD 21.69B 1.98B Mar/2026
Lakefront Biotherapeutics EUR 66.8M 21.06M Mar/2026
Lonza CHF 719M 188M Dec/2025
Merck EUR 2.33B 77M Dec/2025
Merck USD 5.33B 9.24B Mar/2026
Novartis USD 6.88B 4.56B Mar/2026
Novartis USD 9.56B 2.9B Sep/2025
Novo Nordisk A/S DKK 18.44B 5.78B Jun/2025
Orion EUR 160.9M 63.3M Dec/2025
Pfizer USD 1.7B 561M Mar/2026
Philips EUR 2.79B 882M Dec/2025
Recordati EUR 428.82M 42.64M Dec/2025
Regeneron Pharmaceuticals USD 2.96B 15.9B Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
UCB EUR 1.57B 1.14B Dec/2024